Table I.
Patient Demographics and Baseline Characteristics
| Parameter | Darusentan (n=76) | Placebo (n=39) | Total (n=115) |
|---|---|---|---|
| Age, y | 62±10 | 63±11 | 62±10 |
| Male sex, No. (%) | 43 (57) | 25 (64) | 68 (59) |
| Race, No. (%) | |||
| White | 53 (70) | 29 (74) | 82 (71) |
| Black | 23 (30) | 9 (23) | 32 (28) |
| American Indian or Alaska Native | 0 | 1 (3) | 1 (1) |
| Weight, kg | 91.2±16.3 | 96.6±17.3 | 93.0±16.7 |
| Body mass index, kg/m2 | 31.2±5.0 | 32.6±4.8 | 31.7±4.9 |
| Estimated GFR, mL/min/1.73 m2 | 74.2±24.3 | 79.3±26.3 | 75.9±25.0 |
| Diabetes and/or chronic kidney disease, No. (%) | 46 (61) | 24 (62) | 70 (61) |
| Diabetes, No. (%) | 36 (47) | 19 (49) | 55 (48) |
| Chronic kidney disease, No. (%) | 20 (26) | 9 (23) | 29 (25) |
| Sitting SBP, mm Hg | 149.6±12.7 | 149.0±13.9 | 149.4±13.1 |
| Sitting DBP, mm Hg | 82.4±12.4 | 79.7±14.1 | 81.5±13.0 |
| Mean 24‐hour SBP, mm Hg | 136.0±13.7 | 138.1±15.8 | 136.7±14.4 |
| Mean 24‐hour DBP, mm Hg | 77.6±12.1 | 74.7±11.3 | 76.6±11.9 |
| Sitting heart rate, bpm | 66.7±10.6 | 68.7±11.2 | 67.4±10.8 |
| Qualifying concomitant antihypertensives, No. (%) | |||
| Diuretics | 76 (100) | 39 (100) | 115 (100) |
| Calcium channel blockers | 49 (65) | 28 (72) | 77 (67) |
| β‐Blockers | 37 (49) | 17 (44) | 54 (47) |
| ACEIs or ARBs | 71 (93) | 36 (92) | 107 (93) |
| Data are presented as mean ± SD unless otherwise indicated. Abbreviations: ACEI, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; bpm, beats per minute; DBP, diastolic blood pressure; GFR, glomerular filtration rate; SBP, systolic blood pressure. | |||